The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy

Authors: Tian He, Bin Xu, Lu-Na Wang, Zi-Yi Wang, Huan-Chen Shi, Cheng-Jie Zhong, Xiao-Dong Zhu, Ying-Hao Shen, Jian Zhou, Jia Fan, Hui-Chuan Sun, Bo Hu, Cheng Huang

Source: Biomarker Research, Vol 13, Iss 1, Pp 1-13 (2025)

Subject Terms: Hepatocellular carcinoma, Immune-based therapy, Atezolizumab-bevacizumab, Systemic immune-inflammation index (SII), Prognosis, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://doaj.org/toc/2050-7771

Access URL: https://doaj.org/article/874c252a2a38456696acb5bf679cc4bb

Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy

Authors: Hironori Ochi, Masayuki Kurosaki, Takaaki Tanaka, Nobuharu Tamaki, Kaoru Tsuchiya, Yutaka Yasui, Hiroyuki Marusawa, Toshifumi Tada, Shinichiro Nakamura, Takehiro Akahane, Eisuke Okamoto, Haruhiko Kobashi, Hirotaka Arai, Michiko Nonogi, Namiki Izumi

Source: JGH Open, Vol 9, Iss 1, Pp n/a-n/a (2025)

Subject Terms: atezolizumab‐bevacizumab, hepatocellular carcinoma, lenvatinib, proteinuria, Diseases of the digestive system. Gastroenterology, RC799-869

File Description: electronic resource

Relation: https://doaj.org/toc/2397-9070

Access URL: https://doaj.org/article/f63456ec468b49ae95e314cd31f7e7be

A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion

Authors: Masatoshi Kudo

Source: Liver Cancer, Vol 10, Iss 6, Pp 539-544 (2021)

Subject Terms: hepatocellular carcinoma, intermediate-stage hepatocellular carcinoma, atezolizumab/bevacizumab curative conversion, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.karger.com/Article/FullText/519749; https://doaj.org/toc/2235-1795; https://doaj.org/toc/1664-5553

Access URL: https://doaj.org/article/3b527f3351db4053af3b26a90b2bfcec

Data Favor Adjuvant Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma

Authors: By:Nicholas Wrigley

Source: CancerNetwork (USA), January 23, 2023 News, 2pp